Price Alert

AtriCure Inc. (ATRC)

NASDAQ: ATRC · Real-Time Price · USD

35.94

-0.13 (-0.36%)

At close: Aug 20, 2025, 3:59 PM

-0.36% (1D)

Bid	35.78
Market Cap	1.79B
Revenue (ttm)	499.95M
Net Income (ttm)	-36.36M
EPS (ttm)	-0.77
PE Ratio (ttm)	-46.68
Forward PE	-162.89
Analyst	Buy

Ask	36.19
Volume	9,356
Avg. Volume (20D)	529,019
Open	36.19
Previous Close	36.07
Day's Range	35.90 - 36.19
52-Week Range	23.97 - 43.11
Beta	1.62

About ATRC

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol ATRC

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for ATRC stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

AtriCure Inc. is scheduled to release its earnings on Oct 28, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

3 weeks ago

+10.72%

AtriCure shares are trading higher after the compa... Unlock content with Pro Subscription

3 weeks ago

-4.49%

AtriCure shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY25 guidance above estimates.

News

19 hours ago · businesswire.com

AtriCure to Participate in the 2025 Wells Fargo Healthcare Conference

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o...

3 weeks ago · fool.com

AtriCure (ATRC) Q2 Revenue Jumps 17%

3 weeks ago · seekingalpha.com

AtriCure, Inc. (ATRC) Q2 2025 Earnings Call Transcript

AtriCure, Inc. (NASDAQ:ATRC ) Q2 2025 Earnings Conference Call July 29, 2025 4:30 PM ET Company Participants Angela L. Wirick - Chief Financial Officer Michael H.

3 weeks ago · zacks.com

AtriCure (ATRC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for AtriCure (ATRC) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street ...

3 weeks ago · zacks.com

AtriCure (ATRC) Reports Q2 Loss, Tops Revenue Estimates

AtriCure (ATRC) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.17 per share a year ago.

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain ...